Vemurafenib, a BFAF inhibitor, has shown prolonged efficacy in patients with BRAF V600-mutant Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) [66]. This evidence concerns the gene BRAF and Langerhans cell histiocytosis.